Idarucizumab (Praxbind®)

This is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate protective clothing.		
CAUTION: High Administration Risk Rating		
Form & Storage	Praxbind (2.5g/50mL)	Store at 2–8°C in original packaging. Do not freeze.
Reconstitution	Already in solution	
Compatibility & Stability	Compatible fluids not needed, already in solution **From a microbiological point of view, should be used immediately**; Inspect for particulate matter and discolouration prior to administration.	
Administration	Praxbind (2 vials of 2.5 g/50 mL) is administered intravenously as two consecutive infusions over 5 to 10 minutes each or as a bolus injection over 3-5 minutes. **IV Infusion (preferred)** Administer a 5g dose as two consecutive infusions of 2.5g per 50ml **over 5 to 10 minutes each** (two bottles of 2.5g administered one immediately after another) using a **vented administration line.**  To prevent possible air embolism, bottles must be vented in one of two ways: directly by means of a filter needle into the bottle which goes through the rubber stopper and opens into the air, or using a vented administration line. **IV bolus** May be given by iv bolus over 3-5 minutes, infusion preferred due to volume (100mL per dose)	
Documentation Requirements	In order to improve the traceability of biological medicinal products, **the name and batch number of the administered product should be clearly recorded**	
Additional Information	• The recommended dose is 5 g idarucizumab (2 vials of 2.5 g/50 mL) • Administration of a second 5 g dose of idarucizumab may be considered in the following situations: - recurrence of clinically relevant bleeding together with prolonged clotting times, or - if potential re-bleeding would be life-threatening and prolonged clotting times are observed, or - patients require a second emergency surgery/urgent procedure and have prolonged clotting times. **Restarting Antithrombotic therapy** • Pradaxa (dabigatran etexilate) treatment can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate haemostasis has been achieved.	

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542

	• After administration of idarucizumab, other antithrombotic therapy (e.g. low-molecular weight heparin) can be started at any time, if the patient is clinically stable and adequate haemostasis has been achieved. • Absence of antithrombotic therapy exposes patients to the thrombotic risk of their underlying disease or condition.

Information provided relates to Praxbind® manufactured by Boehringer Ingelheim